


## WHAT IS CLAIMED IS

1. A compound of formula (I)



or a therapeutically acceptable salt thereof, wherein

$R^1$  is selected from the group consisting of alkyl, alkylsulfanylalkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, (heterocycle)alkyl, and hydroxyalkyl; and

$R^2$  is selected from the group consisting of hydrogen, alkenyl, alkyl, alkylcarbonyloxyalkyl, alkylcarbonylalkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocycle, and (heterocycle)alkyl.

2. The compound of claim 1 wherein  $R^2$  is hydrogen.

3. The compound of claim 2 wherein  $R^1$  is alkylsulfanylalkyl.

4. The compound of claim 3 selected from the group consisting of  
(2*RS*,3*R*)-3-amino-2-hydroxy-5-(methylsulfanyl)pentanoic acid;  
(2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoic acid;  
(2*RS*,3*R*)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoic acid; and  
(2*RS*,3*R*)-3-amino-5-(*tert*-butylsulfanyl)-2-hydroxypentanoic acid.

5. The compound of claim 2 wherein  $R^1$  is selected from the group consisting of arylalkyl, cycloalkyl, (cycloalkyl)alkyl, and hydroxyalkyl.

6. The compound of claim 5 selected from the group consisting of  
(2*RS*,3*R*)-3-amino-4-cyclohexyl-2-hydroxybutanoic acid;  
(2*RS*,3*R*)-3-amino-3-cyclohexyl-2-hydroxypropanoic acid;  
(2*RS*,3*R*)-3-amino-2-hydroxy-5-phenylpentanoic acid;  
(2*S*,3*R*,4*S*)-3-amino-2-hydroxy-4-(3-hydroxypropyl)-7-methyloctanoic acid; and  
(2*S*,3*R*)-3-amino-2-hydroxy-6-phenylhexanoic acid.

7. The compound of claim 1 wherein  $R^2$  is arylalkyl.

8. The compound of claim 7 wherein  $R^1$  is alkylsulfanylalkyl.

9. The compound of claim 8 selected from the group consisting of  
(2*S*)-2-(methylamino)-2-(1-naphthyl)ethyl (2*S*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
(2*R*)-2-(methylamino)-2-(1-naphthyl)ethyl (2*S*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
5 2-(methylamino)-2-(1-naphthyl)propyl (3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
and  
benzyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate.

10. The compound of claim 7 wherein R<sup>1</sup> is selected from the group consisting of arylalkyl, cycloalkyl, and (cycloalkyl)alkyl.

11. The compound of claim 10 selected from the group consisting of  
benzyl (2*S*,3*R*)-3-amino-3-cyclopentyl-2-hydroxypropanoate;  
benzyl (2*S*,3*R*)-3-amino-3-cycloheptyl-2-hydroxypropanoate;  
(2*R*)-2-(methylamino)-2-(1-naphthyl)ethyl (2*S*,3*R*)-3-amino-4-cyclohexyl-2-hydroxybutanoate; and  
5 (2*R*)-2-(methylamino)-2-(1-naphthyl)ethyl (2*S*,3*R*)-3-amino-2-hydroxy-5-phenylpentanoate.

12. The compound of claim 1 wherein R<sup>2</sup> is alkyl.

13. The compound of claim 12 selected from the group consisting of  
methyl (3*R*)-3-amino-2-hydroxy-5-(methylsulfanyl)pentanoate;  
methyl (2*RS*,3*R*)-3-amino-4-cyclohexyl-2-hydroxybutanoate;  
methyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
5 butyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
isopropyl (2*S*,3*R*)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoate;  
isopropyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
*sec*-butyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate; and  
*sec*-butyl (2*RS*,3*R*)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoate.

14. The compound of claim 1 wherein R<sup>2</sup> is selected from the group consisting of alkylcarbonyloxyalkyl, aryl, heterocycle, and (heterocycle)alkyl.

15. The compound of claim 14 selected from the group consisting of

(1*S*,2*R*)-2-amino-2,3-dihydro-1*H*-inden-1-yl (2*RS*,3*R*)-3-amino-4-cyclohexyl-2-hydroxybutanoate;  
[(2,2-dimethylpropanoyl)oxy]methyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-  
5 hydroxypentanoate;  
(1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)methyl (2*RS*,3*R*)-3-amino-5-(ethylsulfanyl)-2-hydroxypentanoate;  
[(2,2-dimethylpropanoyl)oxy]methyl (2*S*,3*R*)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoate;  
10 (1,3-dioxo-1,3-dihydro-2*H*-isoindol-2-yl)methyl (2*S*,3*R*)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoate; and  
3-oxo-1,3-dihydro-2-benzofuran-1-yl (2*S*,3*R*)-3-amino-2-hydroxy-5-(isopropylsulfanyl)pentanoate.

16. A pharmaceutical composition comprising a compound of claim 1 or a therapeutically acceptable salt thereof, in combination with a therapeutically acceptable carrier.

17. A method of inhibiting angiogenesis in a mammal in recognized need of such treatment comprising administering to the mammal a pharmaceutically acceptable amount of a compound of claim 1.

18. A method for treating cancer in a patient in recognized need of such treatment comprising administering to the patient a therapeutically acceptable amount of a compound of claim 1, or a therapeutically acceptable salt thereof.